The discovery and production of therapeutic antibodies support a market valued at approximately $400 billion. In 2023, over 100 monoclonal antibodies were in clinical trials, but the production of these antibodies remains a significant bottleneck. Typical antibody discovery timelines using the standard mouse hybridoma platform are around six months, with no guarantee of success. This inefficiency arises because standard immunogens, such as proteins or peptides, are quickly eliminated by the immune system. Proteins are recognized as foreign, and even short peptides have a half-life of only 2-30 minutes before being filtered out. Consequently, the discovery process can cost up to £100,000 per antibody with uncertain outcomes. As antibody therapies become more specific and complex, there is a pressing need for innovative solutions that produce high-quality antibodies more cost-effectively and quickly. Antigenesis Biologics has addressed these challenges by developing a state-of-the-art discovery platform that halves production times and costs, enabling the manufacture of highly specific and complex antibodies. To achieve this, Antigenesis Biologics has subcontracted Queen's University Belfast to assist in creating a discovery platform utilising mRNA technology to produce antibodies from proteins synthesised within cells (_in vivo_). Traditionally, mRNA technologies have been delivered using lipid nanoparticles (LNP), which, while effective for vaccines, elicit immune responses against the lipids, making them sub-optimal for antibody production. We have developed a novel peptide that binds mRNA of any size and type into nanoparticles. When injected _in vivo_, these nanoparticles specifically target antigen-presenting cells, triggering an immune response and antibody production. This technology reduces immunisation timelines from the industry's standard three months to just 21 days. Coupled with Antigenesis's extensive experience of over 30 years in protein sequence design using AI technologies, this innovation results in a first-of-its-kind discovery platform. The establishment of this discovery engine will enable Antigenesis to rapidly develop robust revenue streams, achieving financial self-sufficiency. This investment represents a significant commercial opportunity, driving growth and innovation for Antigenesis. It also enhances Northern Ireland's and the UK's positions in the gene therapy market, offering potential for global expansion.